The tweet was deleted by the author.
But we saved everything 🙂.
CVRx has announced the publication of the BENEFIT-HF trial design paper in the Journal of Cardiac Failure.
The article presents the methodology for a prospective, randomized, controlled, multicenter clinical study examining heart failure interventions. The trial is backed by CMS Category B IDE coverage, a pathway designed to support innovative medical devices in clinical evaluation. The newly published paper will serve as a reference for stakeholders and researchers monitoring the progress of next-generation heart failure therapies.
CVRx recently celebrated its 25th Barostim implant milestone at UNC Medical Center Chapel Hill. The company also announced a national agreement with Humana to cover Barostim therapy through Medicare Advantage plans. These developments come as CVRx advances clinical research in heart failure interventions.